Please ensure Javascript is enabled for purposes of website accessibility

Why Greenwich LifeSciences Stock Tanked Today

By Keith Speights - Updated Apr 12, 2021 at 4:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drop came despite the clinical-stage biotech announcing good news over the weekend.

What happened

Shares of Greenwich LifeSciences (GLSI -1.70%) were tanking 27.8% as of 3:34 p.m. EDT on Monday. The huge drop came after the company published a poster over the weekend at the American Association for Cancer Research (AACR) Annual Meeting showing five-year immune response data from a phase 2b study of immunotherapy GP2.

So what

You might think that Greenwich's phase 2 results were horrible after seeing the biotech stock plummet today. That wasn't the case, however. The company reported that patients with HER2-positive breast cancer receiving GP2 had a 100% disease-free survival rate over five years.

Test tube rack with a broken test tube spilling a green solution.

Image source: Getty Images.

So what's behind today's sell-off? Perhaps the best explanation is that we're seeing the old adage "buy the rumor, sell the news" at work. Greenwich's share price jumped more than 50% in the week leading up to the AACR meeting. 

Also, stocks with unusually low floats can have some wild and unexpected swings at times if big shareholders decide to buy or sell. Greenwich's float is only around 2.8 million shares.

Now what

Greenwich LifeSciences now plans to advance GP2 into a phase 3 clinical study. Based on the data from the phase 2 study, the company thinks that monitoring immune response will be a key part of its late-stage trial. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Greenwich LifeSciences, Inc. Stock Quote
Greenwich LifeSciences, Inc.
$9.81 (-1.70%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.